All In Biotech

Drug Trial Radar · NCT02023567

Objective Diagnostic Markers and Personalized Intervention in MDD Patients

The Establishment of the Objective Diagnostic Markers and Personalized Medical Intervention in Patients With Major Depressive Disorders (MDD)

Last checked: Nov 19, 2026Latest source record: May 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

2,400

Planned (sponsor's estimate)

Start

Nov 2013

Primary completion

Dec 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Peking UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Capital Medical University; Peking Union Medical College Hospital; Tianjin Medical University General Hospital; Tianjin Anding Hospital; The First Hospital of Hebei Medical University; First Hospital of China Medical University; Dalian Seventh People's Hospital; The First Affiliated Hospital of Shanxi Medical University
First posted
Dec 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Major depressive disorder (MDD) is one of the most common psychiatric disorders, with high recurrence rate, suicide rate and disability rate. It's reported that the global burden caused by MDD will be up to the second rank among all the disease burdens by 2020. China is also confronted with the daunting challenges against MDD. It's assessed that the monthly incidence of MDD is 6.1%, non-hospitalizing rate reaches up to 92% and the non-treatment rate is approximate 95%. However, to date, the pathogenesis of MDD is obscure and the current therapies don't work well. Therefore, it's urgent and critical to elucidate the pathogenesis of MDD, to develop early diagnostic criteria and effective intervention in MDD. Considering the diversity of weights on genetic factor and environmental factor in MDD, in this project, the investigators aim firstly to explore the effect of "genetic-environmental interaction"on the pathogeny of MDD for classifying MDD into "genetic type", "environmental type" and "others" based on a case-control study. We next conduct the neurobiological, neurocognitive and psycho-behavioral assessments among MDD, schizophrenia and healthy groups to screen the salient endophenotypes for establishing the diagnostic models of MDD . The investigators further analyse the changes of these indicators after 8 weeks'medication to select the potential predictors for therapeutic evaluations and interventional options in MDD patients. Finally, the investigators continue a 2-year follow-up study to test and verify the predictors of prognosis in MDD patients.

Conditions

  • Depressive Disorder, Major

Interventions

  • SSRIsDrug

    fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The changes of HAMD total score at 8 weeks from baselineTime frame: week 0,2,4,8

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Anding Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Active not recruiting

  • Peking University Sixth Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Hebei Medical University First Hospital

    Shijiazhuang, Hebei, China · Active not recruiting

  • Dalian Seventh People's Hospital

    Dalian, Liaoning, China · Active not recruiting

  • First Hospital of China Medical University

    Shenyang, Liaoning, China · Active not recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Active not recruiting

  • Tianjin Anding Hospital

    Tianjin, Tianjin Municipality, China · Active not recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.